SYNB 1020

Drug Profile

SYNB 1020

Alternative Names: SYNB-1020

Latest Information Update: 25 Jul 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Synlogic
  • Class Probiotics
  • Mechanism of Action Ammonia scavengers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Inborn urea cycle disorders
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Inborn urea cycle disorders
  • Preclinical Hyperammonaemia

Most Recent Events

  • 26 Jun 2017 Preclinical trials in Hyperammonaemia in USA before June 2017 (PO)
  • 26 Jun 2017 SYNB 1020 receives Fast Track designation for Hyperammonaemia [PO] in USA
  • 19 Jun 2017 Synlogic plans a phase I trial for Hyperammonaemia in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top